201 related articles for article (PubMed ID: 12578357)
1. Mutational analysis of the complex of human RNase inhibitor and human eosinophil-derived neurotoxin (RNase 2).
Teufel DP; Kao RY; Acharya KR; Shapiro R
Biochemistry; 2003 Feb; 42(6):1451-9. PubMed ID: 12578357
[TBL] [Abstract][Full Text] [Related]
2. Superadditive and subadditive effects of "hot spot" mutations within the interfaces of placental ribonuclease inhibitor with angiogenin and ribonuclease A.
Chen CZ; Shapiro R
Biochemistry; 1999 Jul; 38(29):9273-85. PubMed ID: 10413501
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the interactions of human ribonuclease inhibitor with angiogenin and ribonuclease A by mutagenesis: importance of inhibitor residues inside versus outside the C-terminal "hot spot".
Shapiro R; Ruiz-Gutierrez M; Chen CZ
J Mol Biol; 2000 Sep; 302(2):497-519. PubMed ID: 10970748
[TBL] [Abstract][Full Text] [Related]
4. Molecular recognition of human eosinophil-derived neurotoxin (RNase 2) by placental ribonuclease inhibitor.
Iyer S; Holloway DE; Kumar K; Shapiro R; Acharya KR
J Mol Biol; 2005 Apr; 347(3):637-55. PubMed ID: 15755456
[TBL] [Abstract][Full Text] [Related]
5. Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A.
Chen CZ; Shapiro R
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1761-6. PubMed ID: 9050852
[TBL] [Abstract][Full Text] [Related]
6. Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction.
Suzuki M; Saxena SK; Boix E; Prill RJ; Vasandani VM; Ladner JE; Sung C; Youle RJ
Nat Biotechnol; 1999 Mar; 17(3):265-70. PubMed ID: 10096294
[TBL] [Abstract][Full Text] [Related]
7. Toward rational design of ribonuclease inhibitors: high-resolution crystal structure of a ribonuclease A complex with a potent 3',5'-pyrophosphate-linked dinucleotide inhibitor.
Leonidas DD; Shapiro R; Irons LI; Russo N; Acharya KR
Biochemistry; 1999 Aug; 38(32):10287-97. PubMed ID: 10441122
[TBL] [Abstract][Full Text] [Related]
8. Structural features that determine the enzymatic potency and specificity of human angiogenin: threonine-80 and residues 58-70 and 116-123.
Shapiro R
Biochemistry; 1998 May; 37(19):6847-56. PubMed ID: 9578571
[TBL] [Abstract][Full Text] [Related]
9. Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein.
Slifman NR; Loegering DA; McKean DJ; Gleich GJ
J Immunol; 1986 Nov; 137(9):2913-7. PubMed ID: 3760576
[TBL] [Abstract][Full Text] [Related]
10. Dissection of binding interactions in the complex between the anti-lysozyme antibody HyHEL-63 and its antigen.
Li Y; Urrutia M; Smith-Gill SJ; Mariuzza RA
Biochemistry; 2003 Jan; 42(1):11-22. PubMed ID: 12515535
[TBL] [Abstract][Full Text] [Related]
11. Eosinophil cationic protein cDNA. Comparison with other toxic cationic proteins and ribonucleases.
Barker RL; Loegering DA; Ten RM; Hamann KJ; Pease LR; Gleich GJ
J Immunol; 1989 Aug; 143(3):952-5. PubMed ID: 2745977
[TBL] [Abstract][Full Text] [Related]
12. Role of catalytic and non-catalytic subsite residues in ribonuclease activity of human eosinophil-derived neurotoxin.
Sikriwal D; Seth D; Batra JK
Biol Chem; 2009 Mar; 390(3):225-34. PubMed ID: 19090717
[TBL] [Abstract][Full Text] [Related]
13. Roles of N-terminal region residues Lys11, Arg13, and Arg24 of antithrombin in heparin recognition and in promotion and stabilization of the heparin-induced conformational change.
Schedin-Weiss S; Desai UR; Bock SC; Olson ST; Björk I
Biochemistry; 2004 Jan; 43(3):675-83. PubMed ID: 14730971
[TBL] [Abstract][Full Text] [Related]
14. A mutational analysis of binding interactions in an antigen-antibody protein-protein complex.
Dall'Acqua W; Goldman ER; Lin W; Teng C; Tsuchiya D; Li H; Ysern X; Braden BC; Li Y; Smith-Gill SJ; Mariuzza RA
Biochemistry; 1998 Jun; 37(22):7981-91. PubMed ID: 9609690
[TBL] [Abstract][Full Text] [Related]
15. An insertion in loop L7 of human eosinophil-derived neurotoxin is crucial for its antiviral activity.
Sikriwal D; Seth D; Parveen S; Malik A; Broor S; Batra JK
J Cell Biochem; 2012 Oct; 113(10):3104-12. PubMed ID: 22581709
[TBL] [Abstract][Full Text] [Related]
16. Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A.
Rutkoski TJ; Kurten EL; Mitchell JC; Raines RT
J Mol Biol; 2005 Nov; 354(1):41-54. PubMed ID: 16188273
[TBL] [Abstract][Full Text] [Related]
17. Both aromatic and cationic residues contribute to the membrane-lytic and bactericidal activity of eosinophil cationic protein.
Carreras E; Boix E; Rosenberg HF; Cuchillo CM; Nogués MV
Biochemistry; 2003 Jun; 42(22):6636-44. PubMed ID: 12779318
[TBL] [Abstract][Full Text] [Related]
18. Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth.
Leonidas DD; Shapiro R; Allen SC; Subbarao GV; Veluraja K; Acharya KR
J Mol Biol; 1999 Jan; 285(3):1209-33. PubMed ID: 9918722
[TBL] [Abstract][Full Text] [Related]
19. Contributions of interfacial residues of human Interleukin15 to the specificity and affinity for its private alpha-receptor.
Sakamoto S; Caaveiro JM; Sano E; Tanaka Y; Kudou M; Tsumoto K
J Mol Biol; 2009 Jun; 389(5):880-94. PubMed ID: 19406127
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional crystal structure of human eosinophil cationic protein (RNase 3) at 1.75 A resolution.
Mallorquí-Fernández G; Pous J; Peracaula R; Aymamí J; Maeda T; Tada H; Yamada H; Seno M; de Llorens R; Gomis-Rüth FX; Coll M
J Mol Biol; 2000 Jul; 300(5):1297-307. PubMed ID: 10903870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
